Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) (“Deciphera”) is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology, Deciphera designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through its patient-inspired approach, Deciphera seeks to develop a broad portfolio of innovative medicines to improve treatment outcomes. QINLOCK, its switch-control tyrosine kinase inhibitor, was engineered using Deciphera’s proprietary drug discovery platform and developed for the treatment of fourth-line advanced GIST (gastrointestinal stromal tumor). QINLOCK is approved in Australia, Canada, China, the EU, Hong Kong, Switzerland, Taiwan, the United Kingdom and the United States, for the treatment of fourth-line GIST.